Endolysin treatment against Staphylococcus aureus in adults with atopic dermatitis: A randomized controlled trial - 05/09/19
Doi : 10.1016/j.jaci.2019.05.020
Jill de Wit, MD a, Joan E.E. Totté, MD, PhD a, ∗, Minke M.F. van Mierlo, MD a, ∗, Joyce van Veldhuizen, MD a, Martijn B.A. van Doorn, MD, PhD a, Frank H.J. Schuren, PhD b, Sten P. Willemsen, PhD c, Luba M. Pardo, MD, PhD a, Suzanne G.M.A. Pasmans, MD, PhD a 
a Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
b TNO, Microbiology and Systems Biology Group, Zeist, The Netherlands
c Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| The Department of Dermatology of the Erasmus MC University Medical Center Rotterdam received an unrestricted grant from Micreos Human Health, The Netherlands. |
|
| Disclosure of potential conflict of interest: M. B. A. van Doorn has received financial support from Cutanea Life Sciences (investigator). S. G. M. A. Pasmans has received an unrestricted grant from Micreos Human Health for her department. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2019
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 144 - N° 3
P. 860-863 - septembre 2019 Retour au numéro
Article précédent
- Genetic risk scores do not improve asthma prediction in childhood
- F. Nicole Dijk, Charlotte Folkersma, Olena Gruzieva, Ashish Kumar, Alet H. Wijga, Ulrike Gehring, Inger Kull, Dirkje S. Postma, Judith M. Vonk, Erik Melén, Gerard H. Koppelman
- Janus kinase 1/2 inhibition for the treatment of autoinflammation associated with heterozygous TNFAIP3 mutation
- Ciara M. Mulhern, Ying Hong, Ebun Omoyinmi, Thomas S. Jacques, Felice D'Arco, Cheryl Hemingway, Paul A. Brogan, Despina Eleftheriou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?